Biosplice’s Beaupre becomes CMO at Ideaya

Synthetic lethality play Ideaya Biosciences Inc. (NASDAQ:IDYA) hired Darrin Beaupre as CMO. Beaupre was CMO and head of R&D in oncology at Biosplice Therapeutics Inc., before which he was SVP and head of early oncology development and clinical research at Pfizer Inc. (NYSE:PFE). Ideaya is using its synthetic lethality platform to discover targets and biomarkers to develop oncology therapies. 

Autoimmune disease company Selecta Biosciences Inc. (NASDAQ:SELB) hired Blaine Davis as CFO. Davis was CFO at Protara Therapeutics Inc. (NASDAQ:TARA), and VP, head of investor relations and corporate communications at Insmed Inc. (NASDAQ:INSM). Selecta is developing tolerogenic gene and biologic therapies using its ImmTOR platform...